Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. 2007

Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, USA. ofreudenreich@partners.org

BACKGROUND Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials. OBJECTIVE To examine if adding risperidone to stable yet symptomatic schizophrenia outpatients on optimized clozapine monotherapy improves psychopathology. METHODS We conducted a double-blind placebo-controlled parallel-group trial of a fixed dose of 4 mg/day risperidone added for 6 weeks in 24 outpatients with schizophrenia. RESULTS Subjects who received risperidone showed a non-significant decrease in PANSS total score. The PANSS disorganized thought subscale improved significantly (beta=-3.3079, p=0.047). CONCLUSIONS Our trial does not support the routine addition of risperidone to clozapine in refractory schizophrenia patients. However, much larger trials are needed to conclusively settle the question of added efficacy from this combination.

UI MeSH Term Description Entries
D008297 Male Males
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
December 1997, The British journal of psychiatry : the journal of mental science,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
January 2008, Pharmacopsychiatry,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
July 2018, Therapeutic advances in psychopharmacology,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
January 2005, The American journal of psychiatry,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
May 2011, Journal of psychopharmacology (Oxford, England),
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
February 2014, Journal of clinical psychopharmacology,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
April 2011, Schizophrenia research,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
July 2016, Psychological medicine,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
February 1995, Journal of clinical psychopharmacology,
Oliver Freudenreich, and David C Henderson, and Jared P Walsh, and Melissa A Culhane, and Donald C Goff
May 2008, The Journal of clinical psychiatry,
Copied contents to your clipboard!